1. Home
  2. ADXN vs BCDA Comparison

ADXN vs BCDA Comparison

Compare ADXN & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADXN
  • BCDA
  • Stock Information
  • Founded
  • ADXN 2002
  • BCDA N/A
  • Country
  • ADXN Switzerland
  • BCDA United States
  • Employees
  • ADXN N/A
  • BCDA N/A
  • Industry
  • ADXN Biotechnology: Pharmaceutical Preparations
  • BCDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • ADXN Health Care
  • BCDA Health Care
  • Exchange
  • ADXN Nasdaq
  • BCDA Nasdaq
  • Market Cap
  • ADXN 8.0M
  • BCDA 7.9M
  • IPO Year
  • ADXN N/A
  • BCDA N/A
  • Fundamental
  • Price
  • ADXN $7.75
  • BCDA $2.32
  • Analyst Decision
  • ADXN Strong Buy
  • BCDA Strong Buy
  • Analyst Count
  • ADXN 1
  • BCDA 1
  • Target Price
  • ADXN $30.00
  • BCDA $25.00
  • AVG Volume (30 Days)
  • ADXN 24.1K
  • BCDA 52.0K
  • Earning Date
  • ADXN 03-24-2025
  • BCDA 03-26-2025
  • Dividend Yield
  • ADXN N/A
  • BCDA N/A
  • EPS Growth
  • ADXN N/A
  • BCDA N/A
  • EPS
  • ADXN 0.06
  • BCDA N/A
  • Revenue
  • ADXN $701,260.00
  • BCDA $71,000.00
  • Revenue This Year
  • ADXN N/A
  • BCDA N/A
  • Revenue Next Year
  • ADXN N/A
  • BCDA N/A
  • P/E Ratio
  • ADXN $1.04
  • BCDA N/A
  • Revenue Growth
  • ADXN N/A
  • BCDA N/A
  • 52 Week Low
  • ADXN $6.81
  • BCDA $1.63
  • 52 Week High
  • ADXN $27.90
  • BCDA $8.85
  • Technical
  • Relative Strength Index (RSI)
  • ADXN 48.97
  • BCDA 49.50
  • Support Level
  • ADXN $7.49
  • BCDA $2.12
  • Resistance Level
  • ADXN $7.86
  • BCDA $2.73
  • Average True Range (ATR)
  • ADXN 0.44
  • BCDA 0.23
  • MACD
  • ADXN 0.01
  • BCDA 0.01
  • Stochastic Oscillator
  • ADXN 47.96
  • BCDA 35.82

About ADXN Addex Therapeutics Ltd

Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: